Current Status of the Oral Delivery of Insulin

Khan,Mansoor;Agarwal,Vikas;

Current Status of the Oral Delivery of Insulin

October 2, 2001

By Mansoor A. Khan, RPh, PhD
Vikas Agarwal

News

Article

Pharmaceutical TechnologyPharmaceutical Technology-10-02-2001

Volume 25

Issue 10

Insulin is one of the most popular proteins to be studied for oral delivery. The authors review the current status of the development strategies of insulin drug delivery systems, the various challenges associated with these systems, and how these challenges may be overcome.

External Link - article-4487.pdf

Articles in this issue

Outsourcing Outlook

Effects of Polyethylene Glycol on Morphology, Thermomechanical Properties, and Water Vapor Permeability of Cellulose Acetate-Free Films

Hydrogels for the Controlled Release of Pharmaceutical Proteins

Near-Infrared Inspection Complements Other QC Systems

Safety and Manufacturing Standards

System Optimization for In Situ Fiber-Optic Dissolution Testing: Hydrodynamic Effects, System Performance, and Applications

Current Status of the Oral Delivery of Insulin

Laboratory Equipment Qualification

Filter Integrity Testing in Liquid Applications, Revisited, Part I

360&#176 Feedback &#45 Improving the Selection Process All the Way Around

Entering into an Alliance with Big Pharma: Benchmarks for Drug Delivery Contract Service Providers

Related Content

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report

Susan Haigney

June 30th 2025

Article

The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol

April 30th 2024

Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

3D Rendering of CAR - Chimeric Antigen Receptor Between T-Cell and Cancer Cell | Image Credit: © Alpha Tauri 3D - stock.adobe.com

Priothera Awarded €1.7M in Innovation Contest for Hematologic Malignancy Treatments

Patrick Lavery

June 26th 2025

Article

The company’s mocravimod, a novel oral S1P receptor, is being evaluated for its efficacy as an addition to CAR-T cell therapies.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024

Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.